Status: Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Ashley Towne
Phone: 346.238.2006
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >
Status: Enrolling
Investigator: Brian Bruckner
Study Coordinator: Deborah Barr
Phone: 713.441.3916
This study is evaluating the effectiveness of PleuraFlow System Active Clearance Technology (ACT) in the management of blood evacuation. The Pleuraflow System ACT is a guided wire with a distal loop that rests at the end of a chest tube. The sys ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Prystash
Phone: 713.441.6564
Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >
Status: Open Not Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Michelle Prystash
Phone: 713.441.6564
Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >
Status: Open Not Enrolling
Investigator: Alpesh Shah
Study Coordinator: Patricia Brinegar
Phone: 713.441.3506
This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and OUS. A minimum of 40% of total patients will be enrolled in the US. This study will enroll patient ... Read more >
Status: Enrolling
Investigator: Alan Lumsden
Study Coordinator: Kim Donlon
Phone: 713.441.9394
This prospective, multicenter, single-arm clinical study will further evaluate the safety and effectiveness of Cook's permanent and retrievable inferior vena cava (IVC) filters (specifically, the Günther Tulip® Vena Cava Filter and Cook Celect® ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Prystash
Phone: 713.441.6564
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >
